AdvanCell Closes A$18M Series B Funding Led by Morningside

Series B financing will accelerate growth and advance lead clinical program 212Pb-ADVC001 a best-in-class treatment for metastatic prostate cancer, expand manufacturing platform footprint and progress

Related Keywords

Boston ,Massachusetts ,United States ,Australia ,Shanghai ,China ,London ,City Of ,United Kingdom ,Morningside ,North Lanarkshire ,Australian ,Andrew Adamovich ,Kostenloser Wertpapierhandel ,Adrian Adi Patterson ,Anthony Aiudi ,Kevin Cameron ,Australian Nuclear Science ,Research Development Tax Incentive ,Technology Organisation ,Health Medical Devices Fund ,Targeted Alpha Therapy ,Cancer Treatment ,Alpha Therapies ,Medical Devices Fund ,Targeted Alpha ,Targeted Alpha Therapies ,Bill Ferris ,Scientific Advisory ,Morningside Ventures ,Advancell ,Loses ,Series ,Funding ,